fda halts glp-1 Cheaper Versions: Clinical Implications – PlexusDx 🚨 FDA Moves to Permanently

This reflects a broader industry reality: large pharma companies may prefer acquiring differentiated platforms rather than building from zero in an increasingly crowded race

He says it's seen as a "disease of choice, where people are eating too much and not trying hard enough and don't have enough willpower." But when his patients see how much the medication helps them if diets and excercise don't work, he says they often realize the issue is a medical one not a personal failing

Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4

These synthetic versions are produced by chemical peptide synthesis in a lab similar to synthetic insulin or through recombinant DNA technology

Conservative dosing and careful monitoring are essential.